All In Biotech

Drug Trial Radar · NCT06039254

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

A Multicenter, Non-randomized, Open-label, Parallel-controlled Study to Evaluate the Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

Last checked: Nov 20, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

27

Planned (sponsor's estimate)

Start

Sep 2023

Primary completion

Nov 30, 2023

Study completion Dec 8, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, non-randomized, open-label, parallel-controlled study. The main objective is to evaluate the safety and pharmacokinetics of HRS-1780 in subjects with mild and moderate renal impairment versus healthy subjects, and to provide a basis for dose selection of HRS-1780 in patients with chronic kidney disease.

Conditions

  • Chronic Kidney Disease

Interventions

  • HRS-1780Drug

    Single dose in each arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics-CmaxTime frame: Start of Treatment to end of study (approximately 1 week)
  2. Pharmacokinetics-AUC0-lastTime frame: Start of Treatment to end of study (approximately 1 week)
  3. Pharmacokinetics-AUC0-infTime frame: Start of Treatment to end of study (approximately 1 week)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.